Biochemical characterization and evaluation of cytotoxicity of antistaphylococcal chimeric protein P128
© George et al.; licensee BioMed Central Ltd. 2012
Received: 19 November 2011
Accepted: 8 June 2012
Published: 8 June 2012
Antibiotic resistant S. aureus infection is a global threat. Newer approaches are required to control this organism in the current scenario. Cell wall degrading enzymes have been proposed as antibacterial agents for human therapy. P128 is a novel antistaphylococcal chimeric protein under development against S. aureus for human use which derives its bacterial cell wall degrading catalytic endopeptidase domain from ORF56, the Phage K tail-structure associated enzyme. Lead therapeutic entities have to be extensively characterized before they are assessed in animals for preclinical safety and toxicity. P128 is effective against antibiotic resistant strains as well as against a panel of isolates of global significance. Its efficacy against S. aureus in vivo has been established in our lab. Against this background, this study describes the characterization of this protein for its biochemical properties and other attributes.
We evaluated the requirement or effect of divalent cations and the metal ion chelator, EDTA upon biological activity of P128. As the protein is intended for therapeutic use, we tested its activity in presence of body fluids and antibodies specific to P128. For the same reason, we used standard human cell lines to evaluate cytotoxic effects, if any.
The divalent cations, calcium and magnesium at upto 25 mM and Zinc upto 2.5 mM neither inhibited nor enhanced P128 activity. Incubation of this protein with EDTA, human serum, plasma and blood also did not alter the antibacterial properties of the molecule. No inhibitory effect was observed in presence of hyper-immune sera raised against the protein. Finally, P128 did not show any cytotoxic effect on HEp2 and Vero cells at the highest concentration (5 mg/mL) tested.
The results presented here throw light on several properties of protein P128. Taken together, these substantiate the potential of P128 for therapeutic use against S. aureus. Further development of the protein and conduct of preclinical safety studies in animals is warranted.
Current treatment for staphylococcal infections face multiple challenges including spread of highly virulent strains in the hospital and community environments. Novel therapeutic agents and modalities are becoming a necessity to combat the often invasive infections by these strains [1, 2].
In S. aureus and other Gram-positive bacteria, where the outer membrane is absent, the multilayered peptidoglycan or murein, commonly referred to as the cell wall, represents the limit of the cell. Peptidoglycan is an important component in these bacteria, conferring strength and rigidity to the cell, allowing growth and division, maintaining cell shape, and protecting against osmotic lysis . The peptidoglycan therefore presents an excellent target for antimicrobial action. Murein degrading enzymes that are capable of hydrolyzing the various carbohydrate or protein linkages of the peptidoglycan layer bring about cell death. Such enzymes are produced in eukaryotic and prokaryotic organisms [4–6]. The most appropriate sources of such enzymes would be bacteriophages, which are viruses that prey on bacteria and have co-evolved with their host. P128 is a novel chimeric bacteriophage derived protein that is under development in our laboratory for human therapy against antibiotic resistant staphylococci. P128 has shown potent in vitro bactericidal activity against many staphylococci, including methicillin-resistant S. aureus (MRSA) and has been efficacious as a topical gel in reducing MRSA nasal carriage in an animal model . Efficacy of P128 when administered parenterally, is a key aspect that is currently under investigation.
Various systemic components and prevailing conditions or microenvironments could potentially impact the structure, stability, availability and thereby the biological activity of P128. In case of antibiotics, plasma protein binding is often associated with a loss in antibacterial activity. Loss due to plasma protein binding is shown to be upto 97% in case of Fusidic acid . This loss is upto 90% for Daptomycin and the Minimum Inhibitory Concentration (MIC) of this antibiotic is adversely affected in the presence of human serum with associated clinical failures . In case of antimicrobial peptides (AMPs), it is known that various defensins are partly or completely antagonized by high salt conditions or the presence of plasma proteins in vitro[10, 11]. It is also known that the activity of cationic antimicrobial peptides, such as neutrophil defensins is influenced by various microenvironmental conditions .
Cell wall degrading enzymes are of significantly higher molecular size compared to AMPs. However, they have to face similar challenges in physiological environments that could potentially affect protein folding and stability, or cause inactivation or inhibition of enzymatic activity. Inorganic ions, especially metal ions such as Ca2+, Mg2+ and Zn2+, have been shown to modulate the activity of bacterial cell wall degrading enzymes [13, 14]. The likelihood of degradation of such proteinaceous antibacterials by proteases and neutralization by the immune system  cannot be ignored.
Considering the heterogeneity of biological fluids, understanding the impact of the physiological and biological components in such complex matrices on the activity of P128 would be critical and forms the basis of this work. Bactericidal activity of P128 is tested under various conditions including presence of divalent cations (Ca2+, Mg2+ and Zn2+), EDTA, hyper-immune sera; human serum; plasma; and whole blood.
A key milestone that lead molecules have to reach, for further development as drug candidates, is that they have to be declared ‘safe’ for use . The major challenge that overrides the potent and broad-spectrum activities of many antimicrobial peptides is in fact, the cytotoxicity they may pose [17, 18]. The predictive value of in vitro cytotoxicity tests that reflect ‘basal’ cytotoxicity or adverse effects on basic functions common to all cells, is well-recognized . Understandably, such assays are routinely applied to the evaluation of pharmaceutical molecules as part of the drug discovery process. P128 has been evaluated in the present work for cytotoxicity on two mammalian cell lines.
P128 expression and purification
P128 protein was expressed and purified as described previously .
All strains were cultured in Luria Bertani (LB) broth at 37°C on a rotary shaker (200 rpm). MRSA clinical isolate COL and mupirocin-resistant community-associated MRSA USA300 were used for the bactericidal activity assays. Cell culture media were obtained from HiMedia labs (India).
Bactericidal activity assay
The bactericidal activity of P128 was assessed by a CFU reduction assay. Briefly, cultures of S. aureus were grown in LB broth until absorbance at 600 nm (A600) reached 1.0, and then diluted in LB broth to obtain 1x108 cells/ml. For all assays, 1x108 cells/ml were used, unless otherwise stated. Cells (~1x107 in 100 μl) were treated with purified protein at specified concentrations in 100 μl volume and incubated at 37°C, 200 rpm for 1 h. The residual viable bacterial cells (colony forming units; CFUs) were enumerated by serial dilution and plating on LB agar plates. Dose–response of P128 was evaluated using this assay with varied cell numbers ranging from ~108 to ~101 cells/ml of S. aureus USA300 treated with purified P128 in the concentration range of 0.25 – 10 μg/ml.
Effect of divalent cations and EDTA as modulators of P128 activity
The effect of calcium, magnesium and zinc ions on P128 activity was determined at 37°C in saline, containing different concentrations of Calcium Chloride or Magnesium Chloride or Zinc Acetate.
2 μg of purified P128 was incubated in 10, 20, and 50 mM CaCl2 (Sigma, USA) or MgCl2 (HiMedia) at 37°C for 30 min. Similarly, 2 μg of P128 was incubated in 0.5, 1, 2 and 5 mM Zinc Acetate (Merck, India) at 37°C for 30 min. This was then tested for bactericidal activity on S. aureus USA300 as described. The final salt concentrations in the assay were 5, 10 and 25 mM of CaCl2 or MgCl2 and 0.25, 0.5, 1 and 2.5 mM Zinc Acetate.
The effect of EDTA on P128 activity was determined at 37°C in saline, containing different concentrations of K2 EDTA. 2 μg of purified P128 was incubated in 1.25, 2.5, 5, 10 and 20 mM K2 EDTA (Merck, India) at 37°C for 30 min. This was then tested for bactericidal activity on S. aureus USA300 as described. The final salt concentrations in the assay were 0.625, 1.25, 2.5, 5 and 10 mM K2 EDTA.
P128 activity in human plasma, serum and whole blood
Bactericidal activity of P128 on S. aureus was tested in presence of human biological matrices using the CFU reduction assay format. To prepare serum, 6 ml of whole human blood was collected using a pyrogen free syringe and allowed to clot at ambient temperature. Tubes were centrifuged at 2300 x g for 5 min and serum collected. For whole blood, 6 ml of blood was collected and K2EDTA (Merck, India) was added at a concentration of 1.5 mg/ml. Human plasma was from a commercial source.
2 μg of purified P128 was diluted into 100 μl plasma, serum or whole blood from a 1 mg/ml stock (final assay concentration - 10 μg/ml). 1×107 cells of S. aureus COL or USA300 were resuspended in 100 μl of plasma, serum or whole blood (final assay concentration - 5×107 cells/ml) and treated with P128 that was pre-incubated at ambient temperature for 20 min in the corresponding matrix. Cells incubated in serum, plasma or whole blood without addition of P128 served as controls. Residual CFU were enumerated at the end of 1 h incubation at 37°C.
Effect of hyper-immune sera on P128 activity
P128-specific antibodies were tested for the ability to neutralize the activity of P128. New Zealand White rabbits were immunized with purified P128 using a standard protocol comprising a primary immunization with complete Freund’s adjuvant and three boosts in incomplete Freund’s adjuvant. Enzyme-linked immunosorbent assay (ELISA) titers were>100,000 (reciprocal of the dilution of the inflection point in a typical best-fitted sigmoid curve).
The assay procedure was modified from that described previously . P128 in 0.85% saline (100 μl) was diluted from 100 μg/well – 0.09 μg/well through 11 wells in a microtiter plate. Ten microliters of either hyper-immune rabbit serum, pre-immune serum, or saline was added to each well and incubated at 25°C for 15 min. An equal volume (100 μl) of S. aureus USA300 containing 1x108 cells (final assay concentration - 5x108 cells/ml) was then added to each well. After 30 min at 25°C, 50 μl from each assay well was plated out and residual CFU enumerated. Cells incubated in saline and treated with P128 prepared in saline served as the control for biological activity at each test concentration of the protein in the assay. Cells incubated in saline, pre-immune or hyper-immune sera without the addition of P128 served as cell controls.
In vitro cytotoxicity of P128
The cytotoxicity of P128 was evaluated on HEp2 and Vero cell lines, using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay . HEp2 (ATCC Cat. No.CCL-23, Human epithelial carcinoma) and Vero (ATCC Cat. No. CCL-81, African monkey kidney) were purchased from National Centre for Cell Sciences, Pune, India and were maintained in Eagle’s Minimum Essential Medium (EMEM) (Sigma, USA) supplemented with 10% Fetal Bovine Serum (European Grade FBS, Biological Industries, Israel) and 100 U/mL of ampicillin and 100 μg/mL of streptomycin (Sigma, USA), in a 37°C incubator (NuAire, USA) under an atmosphere of 5% CO2.
Briefly, 1×105 cells were seeded per well in a 96-well flat-bottom microtitre plate (CellStar, Greiner), in 100 μL of complete growth medium and the plate incubated at 37°C for 24 h. After 24 h, fresh growth medium was replenished in the wells. P128 was diluted from an original stock to obtain concentrations ranging from 0.078 to 5 mg/mL, in serum-free EMEM, and 100 μL of each solution was added to respective wells. A 0.5 mg/mL solution of mitomycin C (Sigma, USA; prepared in EMEM) was employed as positive control, and cells treated with 100 μL of EMEM served as negative controls. Each group was evaluated in quadruplicates and the whole experiment repeated twice. The cells were incubated with the solutions for a period of 24 h, followed by removal of the solutions and replenishment of fresh growth medium. Twenty μL of a stock solution of MTT (Sigma, 5 mg/mL in double distilled water) was added per well and the plate incubated in the dark for 4 h at 37°C. This was followed by removal of the contents of the wells and dissolution of the formazan crystals by addition of 150 μL/well of dimethyl sulfoxide (Sigma, USA) solution. Absorbance values at 590 nm were obtained with the help of a UV–vis spectrophotometer (TECAN) within 15 min. The percentage cell viability in each group was calculated in relation to that of the untreated control cells.
A minimum of two experiments were performed for each CFU reduction assay & cytotoxicity assay. Results were obtained as means and standard deviations. Statistical significance was evaluated by one-way analysis of variance (ANOVA) followed by Tukey-Kramer Multiple Comparisons Test wherever appropriate. A value of P<0.05 was considered to be significant. Statistical analysis was done using Microsoft Excel® and GraphPad InStat trial version from GraphPad Software.
Results and discussion
It is well-established that biological activity of enzymes is influenced by various physiological conditions, often referred to as ‘microenvironments’. Extracellular ions (e.g., Ca2+, Mg2+, Zn2+) play an important role as modulators of activity of enzymes [23, 24]. Maintenance of structural and functional stability in tissue or fluid compartments is therefore critical for therapeutic efficacy. The aim of this study was to investigate the influence of various conditions and biological matrices on the bactericidal activity of P128 preliminary to its consideration for parenteral use in humans.
The primary criteria for a therapeutic entity are safety and efficacy, as judged by lack of any form of toxicity when administered along with desired biological activity. Cytotoxicity of antimicrobial peptides is one of the main reasons that prevent the use of this class of molecules as antibacterial drugs. Even antimicrobial peptides that are a part of innate immunity are subject to inhibition in physiological fluids and conditions and show relatively poor activity or are rapidly inactivated [10–12]. It is imperative that molecules of heterologous origin, such as P128 be thoroughly evaluated for potential effects of biological matrices and associated microenvironments on its activity and any form of toxicity the molecule may present to humans.
P128 dose response
In vitro assays have to be carefully designed considering various factors, to enable results and outcomes to be extrapolated to other purposes or translated to further studies. Here, a dose response study was performed, where P128 was tested against S. aureus in a checkerboard assay, correlating the dose-dependence of P128 with variation in target bacterial cell numbers.
Effect of divalent cations and EDTA as modulators of P128 activity
It is well known that inorganic ions and salts are capable of influencing the biological activity of enzymes. The activity of several bacteriolytic enzymes is modulated by different ion species. Bacteriophage endolysin LysH5 shows enhanced activity in the presence of Ca2+ and Mg2+. Other reported bacterial cell wall degrading enzymes have been shown to be dependent on the presence of Ca2+ or Zn2+ for activity [26, 27], or inhibited by one or other ion species such as Mn2+[25, 28]. Zn2+ dependent bactericidal activity against Gram-positive bacteria is exhibited by cell wall degrading enzymes, including lysostaphin which is a zinc-containing metalloprotease .
P128 activity in human plasma, serum and whole blood
We studied the bactericidal activity of P128 in biological fluids in an attempt to simulate the milieu in which P128 could encounter the pathogen in vivo. Strong antimicrobial activities in artificial media or buffer systems in vitro may not be reproducible in complex fluid matrices such as whole blood, plasma, and serum that contain multifactorial components . Additionally, whole blood and other fluid biomatrices may contain peptidases which could potentially degrade proteinaceous molecules, such as P128. The lethal outcome of a peptidoglycan degrading enzyme activity relies upon the occurrence of osmotic lysis when patches of the cell wall are broken down . Complex matrices such as blood may provide osmotically stable environments which could prevent bacterial cell lysis. Such conditions could favor target pathogenic bacteria and thereby reduce their susceptibility to P128. Human sera has been previously reported to have an antagonizing effect on the antibacterial activity of lysostaphin . On the other hand, it is also reported that blood and blood fractions may contain components that complement or potentiate the action of antimicrobial agents resulting in amplified pathogen killing .
Based in part on these concepts, we evaluated the antistaphylococcal activity of P128 in blood and blood fractions.
This favorable behavior of P128 under the tested conditions is of direct relevance to the potential therapeutic applications of the protein.
Effect of hyper-immune sera on P128 activity
One of the potential challenges to the use of heterologous antibacterial proteins for therapy is elicitation of humoral immune response which could reduce or completely block its antibacterial activity, especially if to be administered repeatedly in the course of treatment. However, only a fraction of the antibodies elicited by a complex macromolecular immunogen which possesses biological activity is likely to be directly involved in the neutralizing of that activity. The inhibitory antibodies would be those directed against a limited number of antigenic epitopes localized within the catalytic site or the biologically active conformation of the protein. Sera with high antibody titers (Ab titer of 10240) to lysostaphin were able to neutralize lysostaphin activity in vitro. The effect of hyper-immune serum is reported with other phage derived antibacterial proteins without loss of antibacterial activity [36, 37]. However, even if an inhibitory effect had occurred, it would have been overcome by the high concentration of protein that was used in these studies.
In this work, we used hyper-immune sera raised against P128 in rabbits and evaluated the effect of the sera on the bactericidal activity of P128.
In vitro cytotoxicity of P128
P128 exerts potent and remarkably durable antimicrobial activity as evidenced by comparable bactericidal activity in conventional artificial matrices, such as buffers and saline and in complex matrices or biological fluids including whole blood, plasma and normal and hyper-immune sera.
The antistaphylococcal activity of P128 was not influenced by the presence of divalent cations, Ca2+, Mg2+ or Zn2+ & EDTA.
The protein retains its antistaphylococcal, bactericidal activity under physiological conditions that are likely to be relevant to its therapeutic use in vivo. P128 did not show any cytotoxic effects on mammalian cells.
The authors acknowledge Dr. J. Ramachandran for his support in this work. Authors acknowledge the participation of Renjith Pillai, T. Kamini, Shweta Kumari, Madhavi S., Smitha K.S. and H. Keerthi Sindhu in this work. Authors thank Dr. Barry Kreiswirth, PHRI, New Jersey for providing S. aureus isolates COL and USA300. The authors thank Dr. M. Jayasheela and Dr. S. Padmanabhan for reviewing the manuscript.
- Culos KA, Cannon JP, Grim SA: Alternative agents to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Am J Ther. 2011, in pressGoogle Scholar
- DeRyke CA, Maglio D, Nicolau DP: Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient. Expert Opin Pharmacother. 2005, 6 (6): 873-889. 10.1517/14656518.104.22.1683.PubMedView ArticleGoogle Scholar
- Weidenmaier C, Peschel A: Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. Nat Rev Microbiol. 2008, 6: 276-287. 10.1038/nrmicro1861.PubMedView ArticleGoogle Scholar
- Vollmer W, Joris B, Charlier P, Foster S: Bacterial peptidoglycan (murein) hydrolases. FEMS Microbiol Rev. 2008, 32: 259-286. 10.1111/j.1574-6976.2007.00099.x.PubMedView ArticleGoogle Scholar
- Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ: Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol. 2008, 104: 1-13.PubMedGoogle Scholar
- Dajani R, Zhang Y, Taft PJ, Travis SM, Starner TD, Olsen A, Zabner J, Welsh MJ, Engelhardt JF: Lysozyme secretion by submucosal glands protects the airway from bacterial infection. Am J Resp Cell Mol Bio. 2005, 32: 548-552. 10.1165/rcmb.2005-0059OC.View ArticleGoogle Scholar
- Paul VD, Rajagopalan SS, Sundarrajan S, George SE, Asrani JY, Pillai R, Chikkamadaiah R, Durgaiah M, Sriram B, Padmanabhan S: A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein. BMC Microbiol. 2011, 11: 226-10.1186/1471-2180-11-226.PubMedPubMed CentralView ArticleGoogle Scholar
- Güttler F, Tybring L, Engberg-Pedersen H: Interaction of albumin and fusidic acid. Br J Pharmacol. 1971, 43: 151-160. 10.1111/j.1476-5381.1971.tb07164.x.PubMedPubMed CentralView ArticleGoogle Scholar
- Lee BL, Sachdeva M, Chambers HF: Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother. 1991, 35 (12): 2505-2508. 10.1128/AAC.35.12.2505.PubMedPubMed CentralView ArticleGoogle Scholar
- Marr AK, Gooderham WJ, Hancock REW: Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol. 2006, 6: 468-472. 10.1016/j.coph.2006.04.006.PubMedView ArticleGoogle Scholar
- Wang Y, Agerberth B, Löthgren A, Almstedt A, Johansson J: Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL- 37. J Biol Chem. 1998, 273 (50): 33115-33118. 10.1074/jbc.273.50.33115.PubMedView ArticleGoogle Scholar
- Koo SP, Yeaman MR, Bayer AS: Staphylocidal action of thrombin-induced platelet microbicidal protein is influenced by microenvironment and target cell growth phase. Infect Immun. 1996, 64 (9): 3758-3764.PubMedPubMed CentralGoogle Scholar
- Donovan DM, Lardeo M, Foster-Frey J: Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin. FEMS Microbiol Lett. 2006, 265: 133-139. 10.1111/j.1574-6968.2006.00483.x.PubMedView ArticleGoogle Scholar
- Sugai M, Fujiwara T, Akiyama T, Ohara M, Komatsuzawa H, Inoue S, Suginaka H: Purification and molecular characterization of glycylglycine endopeptidase produced by Staphylococcus capitis EPK1. J Bacteriol. 1997, 179 (4): 1193-1202.PubMedPubMed CentralGoogle Scholar
- Kromminga A, Schellekens H: Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann N Y Acad Sci. 2005, 1050: 257-265. 10.1196/annals.1313.027.PubMedView ArticleGoogle Scholar
- New Drug Application (NDA).http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/default.htm,
- Environmental Protection Agency (EPA): The U.S. Environmental Protection Agency’s strategic plan for evaluating the toxicity of chemicals. 2009,http://www.epa.gov/osa/spc/toxicitytesting/index.htm,Google Scholar
- Kagan BL, Ganz T, Lehrer RI: Defensins: a family of antimicrobial and cytotoxic peptides. Toxicology. 1994, 87: 131-149. 10.1016/0300-483X(94)90158-9.PubMedView ArticleGoogle Scholar
- Barile FA, Dierickx PJ, Kristen U: In vitro cytotoxicity testing for prediction of acute human toxicity. Cell Biol Toxicol. 1994, 10 (3): 155-162. 10.1007/BF00757558.PubMedView ArticleGoogle Scholar
- Vipra AA, Desai SN, Roy P, Patil R, Raj JM, Narasimhaswamy N, Paul VD, Chikkamadaiah R, Sriram B: Antistaphylococcal activity of bacteriophage derived chimeric protein P128. BMC Microbiol. 2012, 12 (1): 41-10.1186/1471-2180-12-41.PubMedPubMed CentralView ArticleGoogle Scholar
- Dajcs JJ, Thibodeaux BA, Girgis DO, Shaffer MD, Delvisco SM, O’Callaghan RJ: Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Invest Ophthalmol Vis Sci. 2002, 43 (12): 3712-3716.PubMedGoogle Scholar
- Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983, 65: 55-63. 10.1016/0022-1759(83)90303-4.PubMedView ArticleGoogle Scholar
- Nelson DL, Cox MM: Enzymes. Lehninger Principles of Biochemistry.Volume 1. Edited by: Lehninger AL. 2005, Freeman WH and Co, New York, 190-237. 4Google Scholar
- Ellison RT, Giehl TJ: Killing of Gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest. 1991, 88: 1080-1091. 10.1172/JCI115407.PubMedPubMed CentralView ArticleGoogle Scholar
- García P, Martínez B, Rodríguez L, Rodríguez A: Synergy between the phage endolysin LysH5 and nisin to kill Staphylococcus aureus in pasteurized milk. Int J Food Microbiol. 2010, 141: 151-155. 10.1016/j.ijfoodmicro.2010.04.029.PubMedView ArticleGoogle Scholar
- Celia LK, Nelson D, Kerr DE: Characterization of a bacteriophage lysin (Ply700) from Streptococcus uberis. Vet Microbiol. 2008, 130: 107-117. 10.1016/j.vetmic.2007.12.004.PubMedView ArticleGoogle Scholar
- Wang M, Liu LH, Wang S, Li X, Lu X, Gupta D, Dziarski R: Human peptidoglycan recognition proteins require zinc to kill both Gram-positive and Gram-negative bacteria and are synergistic with antibacterial peptides. J Immunol. 2007, 178: 3116-3125.PubMedView ArticleGoogle Scholar
- Rodríguez L, Martínez B, Zhou Y, Rodríguez A, Donovan DM, García P: Lytic activity of the virion-associated peptidoglycan hydrolase HydH5 of Staphylococcus aureus bacteriophage vB_SauS-philPLA88. BMC Microbiology. 2011, 11: 138-10.1186/1471-2180-11-138.PubMedPubMed CentralView ArticleGoogle Scholar
- Zygmunt WA, Tavormina PA: Lysostaphin: model for a specific enzymatic approach to infectious disease. Prog Drug Res. 1972, 16: 309-333.PubMedGoogle Scholar
- Ramadurai L, Lockwood KJ, Nadakavukaren MJ, Jayaswal RK: Characterization of a chromosomally encoded glycylglycine endopeptidase of Staphylococcus aureus. Microbiology. 1999, 145: 801-808. 10.1099/13500872-145-4-801.PubMedView ArticleGoogle Scholar
- Park PW, Senior RM, Griffin GL, Broekelmann TJ, Mudd MS, Mecham RP: Binding and degradation of elastin by the staphylolytic enzyme lysostaphin. Int J Biochem Cell Biol. 1995, 27 (2): 139-146. 10.1016/1357-2725(94)00086-Q.PubMedView ArticleGoogle Scholar
- Yeaman MR, Gank KD, Bayer AS, Brass EP: Synthetic peptides that exert antimicrobial activities in whole blood and blood-derived matrices. Antimicrob Agents Chemother. 2002, 46 (12): 3883-3891. 10.1128/AAC.46.12.3883-3891.2002.PubMedPubMed CentralView ArticleGoogle Scholar
- Strominger JL, Ghuysen JM: Mechanisms of enzymatic bacteriolysis. Cell walls of bacteria are solubilized by action of either specific carbohydrases or specific peptidases. Science. 1967, 156: 213-221. 10.1126/science.156.3772.213.PubMedView ArticleGoogle Scholar
- Zygmunt WA, Browder HP, Tavormina PA: Influence of blood and serum on the antistaphylococcal activity of lysostaphin. J Bacteriol. 1966, 91 (2): 725-728.PubMed CentralGoogle Scholar
- Dutcher BS, Reynard AM, Beck ME, Cunningham RK: Potentiation of antibiotic bactericidal activity by normal human serum. Antimicrob Agents Chemother. 1978, 13 (5): 820-826. 10.1128/AAC.13.5.820.PubMedPubMed CentralView ArticleGoogle Scholar
- Loeffler JM, Djurkovic S, Fischetti VA: Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun. 2003, 71 (11): 6199-6204. 10.1128/IAI.71.11.6199-6204.2003.PubMedPubMed CentralView ArticleGoogle Scholar
- Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA: Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010, 54 (4): 1603-1612. 10.1128/AAC.01625-09.PubMedPubMed CentralView ArticleGoogle Scholar
- Zasloff M: Antimicrobial peptides of multicellular organisms. Nature. 2002, 415: 389-395. 10.1038/415389a.PubMedView ArticleGoogle Scholar
- Gordon YJ, Romanowski EG, McDermott AM: A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res. 2005, 30 (7): 505-515. 10.1080/02713680590968637.PubMedPubMed CentralView ArticleGoogle Scholar
- Freshney RI: Measurement of Cytotoxicity and Viability. Culture of Animal Cells. 1987, Alan R. Liss, Inc, New York, 253-254.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.